PF-00547659 for the treatment of Crohn’s disease and ulcerative colitis

References

• Danese S, Fiocchi C. Ulcerative colitis. N Engl J Med. 2011 Nov 03;365(18):1713–1725.
   PubMed Web of Science ®Google Scholar
• Pariente B, Cosnes J, Danese S, et al. Development of the Crohn’s disease digestive damage score, the Lemann score. Inflamm Bowel Dis. 2011 Jun;17(6):1415–1422.
   PubMed Web of Science ®Google Scholar
• Danese S, Fiocchi C. Etiopathogenesis of inflammatory bowel diseases. World J Gastroenterol. 2006 Aug 14;12(30):4807–4812.
   PubMed Web of Science ®Google Scholar
• Engel MA, Neurath MF. New pathophysiological insights and modern treatment of IBD. J Gastroenterol. 2010 Jun;45(6):571–583.
   PubMed Web of Science ®Google Scholar
• Lowenberg M, D’Haens G. Next-generation therapeutics for IBD. Curr Gastroenterol Rep. 2015 Jun;17(6):21.
   PubMedGoogle Scholar
• Allez M, Karmiris K, Louis E, et al. Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects. J Crohns Colitis. 2010 Oct;4(4):355–366.
   PubMed Web of Science ®Google Scholar
• Ben-Horin S, Chowers Y. Review article: loss of response to anti-TNF treatments in Crohn’s disease. Aliment Pharmacol Ther. 2011 May;33(9):987–995.
   PubMed Web of Science ®Google Scholar
• Bouguen G, Peyrin-Biroulet L. Surgery for adult Crohn’s disease: what is the actual risk? Gut. 2011 Sep;60(9):1178–1181.
   PubMed Web of Science ®Google Scholar
• Williet N, Pillot C, Oussalah A, et al. Incidence of and impact of medications on colectomy in newly diagnosed ulcerative colitis in the era of biologics. Inflamm Bowel Dis. 2012 Sep;18(9):1641–1646.
   PubMed Web of Science ®Google Scholar
• Hynes RO. Integrins: versatility, modulation, and signaling in cell adhesion. Cell. 1992 Apr 03;69(1):11–25.
   PubMed Web of Science ®Google Scholar
• Bevilacqua MP. Endothelial-leukocyte adhesion molecules. Annu Rev Immunol. 1993;11:767–804.
   PubMed Web of Science ®Google Scholar
• Binion DG, West GA, Ina K, et al. Enhanced leukocyte binding by intestinal microvascular endothelial cells in inflammatory bowel disease. Gastroenterology. 1997 Jun;112(6):1895–1907.
   PubMed Web of Science ®Google Scholar
• Briskin M, Winsor-Hines D, Shyjan A, et al. Human mucosal addressin cell adhesion molecule-1 is preferentially expressed in intestinal tract and associated lymphoid tissue. Am J Pathol. 1997 Jul;151(1):97–110.
   PubMed Web of Science ®Google Scholar
• Arihiro S, Ohtani H, Suzuki M, et al. Differential expression of mucosal addressin cell adhesion molecule-1 (MAdCAM-1) in ulcerative colitis and Crohn’s disease. Pathol Int. 2002 May-Jun;52(5–6):367–374.
   PubMed Web of Science ®Google Scholar
• Souza HS, Elia CC, Spencer J, et al. Expression of lymphocyte-endothelial receptor-ligand pairs, alpha4beta7/MAdCAM-1 and OX40/OX40 ligand in the colon and jejunum of patients with inflammatory bowel disease. Gut. 1999 Dec;45(6):856–863.
   PubMed Web of Science ®Google Scholar
• Biancheri P, Di Sabatino A, Rovedatti L, et al. Effect of tumor necrosis factor-alpha blockade on mucosal addressin cell-adhesion molecule-1 in Crohn’s disease. Inflamm Bowel Dis. 2013 Feb;19(2):259–264.
   PubMed Web of Science ®Google Scholar
• Polman CH, O’Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006 Mar 02;354(9):899–910.
   PubMed Web of Science ®Google Scholar
• Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med. 2006 Mar 02;354(9):911–923.
   PubMed Web of Science ®Google Scholar
• Yednock TA, Cannon C, Fritz LC, et al. Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature. 1992 Mar 05;356(6364):63–66.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Colombel JF, Enns R, et al. Natalizumab induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2005 Nov 03;353(18):1912–1925.
   PubMed Web of Science ®Google Scholar
• Targan SR, Feagan BG, Fedorak RN, et al. Natalizumab for the treatment of active Crohn’s disease: results of the ENCORE Trial. Gastroenterology. 2007 May;132(5):1672–1683.
   PubMed Web of Science ®Google Scholar
• Gordon FH, Hamilton MI, Donoghue S, et al. A pilot study of treatment of active ulcerative colitis with natalizumab, a humanized monoclonal antibody to alpha-4 integrin. Aliment Pharmacol Ther. 2002 Apr;16(4):699–705.
   PubMed Web of Science ®Google Scholar
• Lobaton T, Vermeire S, Van Assche G, et al. Review article: anti-adhesion therapies for inflammatory bowel disease. Aliment Pharmacol Ther. 2014 Mar;39(6):579–594.
   PubMed Web of Science ®Google Scholar
• Bloomgren G, Richman S, Hotermans C, et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med. 2012 May 17;366(20):1870–1880.
   PubMed Web of Science ®Google Scholar
• Yousry TA, Major EO, Ryschkewitsch C, et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med. 2006 Mar 02;354(9):924–933.
   PubMed Web of Science ®Google Scholar
• Allocca M, Fiorino G, Vermeire S, et al. Blockade of lymphocyte trafficking in inflammatory bowel diseases therapy: importance of specificity of endothelial target. Expert Rev Clin Immunol. 2014 Jul;10(7):885–895.
   PubMed Web of Science ®Google Scholar
• Hesterberg PE, Winsor-Hines D, Briskin MJ, et al. Rapid resolution of chronic colitis in the cotton-top tamarin with an antibody to a gut-homing integrin alpha 4 beta 7. Gastroenterology. 1996 Nov;111(5):1373–1380.
   PubMed Web of Science ®Google Scholar
• Soler D, Chapman T, Yang LL, et al. The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases. J Pharmacol Exp Ther. 2009 Sep;330(3):864–875.
   PubMed Web of Science ®Google Scholar
• Milch C, Wyant T, Xu J, et al. Vedolizumab, a monoclonal antibody to the gut homing alpha4beta7 integrin, does not affect cerebrospinal fluid T-lymphocyte immunophenotype. J Neuroimmunol. 2013 Nov 15;264(1–2):123–126.
   PubMed Web of Science ®Google Scholar
• Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013 Aug 22;369(8):699–710.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2013 Aug 22;369(8):711–721.
   PubMed Web of Science ®Google Scholar
• Sands BE, Feagan BG, Rutgeerts P, et al. Effects of vedolizumab induction therapy for patients with Crohn’s disease in whom tumor necrosis factor antagonist treatment failed. Gastroenterology. 2014 Sep;147(3):618–27 e3.
   PubMed Web of Science ®Google Scholar
• Cepek KL, Parker CM, Madara JL, et al. Integrin alpha E beta 7 mediates adhesion of T lymphocytes to epithelial cells. J Immunol. 1993 Apr 15;150(8 Pt 1):3459–3470.
   PubMed Web of Science ®Google Scholar
• Karecla PI, Bowden SJ, Green SJ, et al. Recognition of E-cadherin on epithelial cells by the mucosal T cell integrin alpha M290 beta 7 (alpha E beta 7). Eur J Immunol. 1995 Mar;25(3):852–856.
   PubMed Web of Science ®Google Scholar
• Schon MP, Arya A, Murphy EA, et al. Mucosal T lymphocyte numbers are selectively reduced in integrin alpha E (CD103)-deficient mice. J Immunol. 1999 Jun 01;162(11):6641–6649.
   PubMed Web of Science ®Google Scholar
• Rutgeerts PJ, Fedorak RN, Hommes DW, et al. A randomised phase I study of etrolizumab (rhuMAb beta7) in moderate to severe ulcerative colitis. Gut. 2013 Aug;62(8):1122–1130.
   PubMed Web of Science ®Google Scholar
• Vermeire S, O’Byrne S, Keir M, et al. Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial. Lancet. 2014 Jul 26;384(9940):309–318.
   PubMed Web of Science ®Google Scholar
• McLean LP, Cross RK. Integrin antagonists as potential therapeutic options for the treatment of Crohn’s disease. Expert Opin Investig Drugs. 2016;25(3):263–273.
   PubMed Web of Science ®Google Scholar
• Pan W-J, Köck K, Rees WA, et al. Clinical pharmacology of AMG 181, a gut-specific human anti-α4β7 monoclonal antibody, for treating inflammatory bowel diseases. Br J Clin Pharmacol. 2014 Dec;78(6):1315–1333.
   PubMed Web of Science ®Google Scholar
• Yoshimura N, Watanabe M, Motoya S, et al. Safety and efficacy of AJM300, an oral antagonist of alpha4 Integrin, in induction therapy for patients with active ulcerative colitis. Gastroenterology. 2015 Dec;149(7):1775–83 e2.
   PubMed Web of Science ®Google Scholar
• Martin SW, Magnusson MO, Matthews IT, et al. W1042 mechanistic population pharmacokinetics (PK) model of PF-00547659, a fully human IgG2 anti-MAdCAM antibody, in ulcerative colitis patients: results of a First in Human (FIH) Study. Gastroenterology. 2009;136(5):A–641.
   Web of Science ®Google Scholar
• Medicine USNLo. Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn’s Disease (OPERA). [NCT01276509]. [ cited 2017 Jul 11]; Available from: https://clinicaltrials.gov/ct2/show/NCT01276509.
   Google Scholar
• Medicine USNLo. A Study To Monitor Long-Term Treatment With PF-00547659 (OPERA II). [NCT01298492]. [ cited 2017 Jul 11]; Available from: https://clinicaltrials.gov/ct2/show/NCT01298492.
   Google Scholar
• Medicine USNLo. Long-Term Safety Of PF-00547659 In Ulcerative Colitis (TURANDOT II). [NCT01771809]. [ cited 2017 Jul 11]; Available from: https://clinicaltrials.gov/ct2/show/NCT01771809.
   Google Scholar
• Pullen N, Molloy E, Carter D, et al. Pharmacological characterization of PF-00547659, an anti-human MAdCAM monoclonal antibody. Br J Pharmacol. 2009 May;157(2):281–293.
   PubMed Web of Science ®Google Scholar
• Sandborn W, Lee SD, Tarabar D, et al. 825 Anti-MAdCAM-1 antibody (PF-00547659) for active refractory Crohn’s disease: results of the OPERA Study. Gastroenterology. 2015;148(4):S–162.
   Web of Science ®Google Scholar
• Vermeire S, Ghosh S, Panes J, et al. The mucosal addressin cell adhesion molecule antibody PF-00547,659 in ulcerative colitis: a randomised study. Gut. 2011 Aug;60(8):1068–1075.
   PubMed Web of Science ®Google Scholar
• Vermeire S, Sandborn WJ, Danese S, et al. Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet. 2017 Jul 08;390(10090):135–144.
   PubMed Web of Science ®Google Scholar
• Stuve O, Cataldi F, Pradhan V, et al. Normal intrathecal leukocyte cell number and composition do not decrease the incidence of post-lumbar puncture headache. J Neuroimmunol. 2017 Sep;15(310):69–71.
   Google Scholar
• Saruta M, Papadakis KA. Lymphocyte homing antagonists in the treatment of inflammatory bowel diseases. Gastroenterol Clin North Am. 2014 Sep;43(3):581–601.
   PubMed Web of Science ®Google Scholar
• Wang M, Kussrow AK, Ocana MF, et al. Physiologically relevant binding affinity quantification of monoclonal antibody PF-00547659 to mucosal addressin cell adhesion molecule for in vitro in vivo correlation. Br J Pharmacol. 2017 Jan;174(1):70–81.
   PubMed Web of Science ®Google Scholar
• Langholz E, Munkholm P, Davidsen M, et al. Colorectal cancer risk and mortality in patients with ulcerative colitis. Gastroenterology. 1992 Nov;103(5):1444–1451.
   PubMed Web of Science ®Google Scholar
• Peyrin-Biroulet L, Harmsen WS, Tremaine WJ, et al. Surgery in a population-based cohort of Crohn’s disease from Olmsted County, Minnesota (1970-2004). Am J Gastroenterol. 2012 Nov;107(11):1693–1701.
   PubMed Web of Science ®Google Scholar
• Sousa P, Allez M. Complications of biologics in inflammatory bowel disease. Curr Opin Gastroenterol. 2015 Jul;31(4):296–302.
   PubMed Web of Science ®Google Scholar
• Adams DH, Eksteen B. Aberrant homing of mucosal T cells and extra-intestinal manifestations of inflammatory bowel disease. Nat Rev Immunol. 2006 Mar;6(3):244–251.
   PubMed Web of Science ®Google Scholar
• Rivera-Nieves J. Strategies that target leukocyte traffic in inflammatory bowel diseases: recent developments. Curr Opin Gastroenterol. 2015 Nov;31(6):441–448.
   PubMed Web of Science ®Google Scholar